These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7494223)

  • 1. NSABP halts B-14 trial: no benefit seen beyond 5 years of tamoxifen use.
    J Natl Cancer Inst; 1995 Dec; 87(24):1829. PubMed ID: 7494223
    [No Abstract]   [Full Text] [Related]  

  • 2. [Tamoxifen (Nolvadex): therapeutic effect in metastasizing breast cancer].
    Mouridsen HT; Palshof T; Patterson J; Battersby L
    Ugeskr Laeger; 1979 Jul; 141(31):2108-13. PubMed ID: 483408
    [No Abstract]   [Full Text] [Related]  

  • 3. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
    Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.
    Fisher B; Costantino JP; Redmond CK; Fisher ER; Wickerham DL; Cronin WM
    J Natl Cancer Inst; 1994 Apr; 86(7):527-37. PubMed ID: 8133536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
    Mamounas EP; Tang G; Paik S; Baehner FL; Liu Q; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Lawrence Wickerham D; Costantino JP; Wolmark N
    Breast Cancer Res Treat; 2018 Feb; 168(1):69-77. PubMed ID: 29128898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
    Mamounas EP; Jeong JH; Wickerham DL; Smith RE; Ganz PA; Land SR; Eisen A; Fehrenbacher L; Farrar WB; Atkins JN; Pajon ER; Vogel VG; Kroener JF; Hutchins LF; Robidoux A; Hoehn JL; Ingle JN; Geyer CE; Costantino JP; Wolmark N
    J Clin Oncol; 2008 Apr; 26(12):1965-71. PubMed ID: 18332472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Ganz PA; Cecchini RS; Julian TB; Margolese RG; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
    Lancet; 2016 Feb; 387(10021):857-65. PubMed ID: 26686960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.
    Tormey DC; Gray R; Falkson HC
    J Natl Cancer Inst; 1996 Dec; 88(24):1828-33. PubMed ID: 8961972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant exemestane therapy after 5 years of tamoxifen: rationale for the NSABP B-33 trial.
    Mamounas EP
    Oncology (Williston Park); 2001 May; 15(5 Suppl 7):35-9. PubMed ID: 11396363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29.
    Chapman JA; Costantino JP; Dong B; Margolese RG; Pritchard KI; Shepherd LE; Gelmon KA; Wolmark N; Pollak MN
    Breast Cancer Res Treat; 2015 Sep; 153(2):353-60. PubMed ID: 26276354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
    Fisher B; Dignam J; Bryant J; DeCillis A; Wickerham DL; Wolmark N; Costantino J; Redmond C; Fisher ER; Bowman DM; Deschênes L; Dimitrov NV; Margolese RG; Robidoux A; Shibata H; Terz J; Paterson AH; Feldman MI; Farrar W; Evans J; Lickley HL
    J Natl Cancer Inst; 1996 Nov; 88(21):1529-42. PubMed ID: 8901851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer.
    Machin D; Andersen KW
    J Natl Cancer Inst; 1997 May; 89(9):659-60. PubMed ID: 9150193
    [No Abstract]   [Full Text] [Related]  

  • 14. The Atlas trial: Tamoxifen for a longer duration for early breast cancer.
    Raina V
    Natl Med J India; 2013; 26(1):4-5. PubMed ID: 24066985
    [No Abstract]   [Full Text] [Related]  

  • 15. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
    Dodwell D; Williamson D
    Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.
    J Natl Cancer Inst; 1996 Nov; 88(21):1543-9. PubMed ID: 8901852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial.
    Westerberg H
    Cancer Treat Rep; 1980 Jan; 64(1):117-21. PubMed ID: 6991101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary data from ongoing adjuvant aromatase inhibitor trials.
    Goss PE
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4397s-4401s; discussion 4411s-4412s. PubMed ID: 11916231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen and breast cancer--from palliation to prevention.
    Rich SE
    Cancer Nurs; 1993 Oct; 16(5):341-6. PubMed ID: 7505194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ.
    Yen TW; Hunt KK; Mirza NQ; Thomas ES; Singletary SE; Babiera GV; Meric-Bernstam F; Buchholz TA; Feig BW; Ross MI; Ames FC; Theriault RL; Kuerer HM
    Cancer; 2004 Mar; 100(5):942-9. PubMed ID: 14983489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.